Search Videos and More

Showing 13 - 24 of 280 results

Previous| 1 | 2 | 3 ...24 |Next


Psilocybin Eases Depression in Patients with Cancer, Study Finds News

Psilocybin Eases Depression in Patients with Cancer, Study Finds

For patients with cancer who are suffering from major depression, treatment with psilocybin plus individual and group psychological support can significantly relieve depressive symptoms, a clinical trial has found. In a companion study led by Dana-Farber Cancer Institute investigators, trial participants said the treatment experience with psilocybin – a hallucinogenic compound derived from certain mushrooms – created a sense of connection, meaning, and transcendence that aided the healing process.
Exploring How CAR T-Cell Therapy May Help More Patients News

Exploring How CAR T-Cell Therapy May Help More Patients

CAR T-cell therapy burst onto the scene as a revolutionary treatment for cancer patients in 2015, when it was introduced in clinical trials primarily for patients with lymphoma and leukemia. Since then, it has transformed the course of disease, primarily for blood cancer patients, with many clinical trials now exploring the approach for solid tumor patients. Through this highly tailored form of immune effector cell (IEC) therapy, typically a patient's own immune cells — known as T cells — are genetically re-engineered to identify and kill cancer cells.
Dana-Farber Research Publication 01.01.2023 News

Dana-Farber Research Publication 01.01.2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber Research Publication 12.15.2022 News

Dana-Farber Research Publication 12.15.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber Research Publication 12.1.2022 News

Dana-Farber Research Publication 12.1.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
American Society of Hematology (ASH) 2023 Symposium

American Society of Hematology (ASH) 2023

Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.
San Antonio Breast Cancer Symposium (SABCS) 2023 Symposium

San Antonio Breast Cancer Symposium (SABCS) 2023

2023 Updates in Neuro-Oncology News

2023 Updates in Neuro-Oncology

Please join us on Zoom for a free symposium on the latest advances in neuro-oncology. Through lecture and discussion, Harvard Medical School faculty will consider how to apply recent clinical research advances to improve the care and outcomes of patients with brain tumors.
Dana-Farber Research Publication 11.15.2022 News

Dana-Farber Research Publication 11.15.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
ESMO Congress 2023 Research Highlights Symposium

ESMO Congress 2023 Research Highlights

Lung, kidney, and neuroendocrine tumor cancer studies led by Dana-Farber presented at ESMO Congress 2023.
Dana-Farber Research Publication 11.01.2023 News

Dana-Farber Research Publication 11.01.2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer Document

Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.

Showing 13 - 24 of 280 results

Previous| 1 | 2 | 3 ...24 |Next